More than 2,000 black men in the UK could die from prostate cancer within the next ten years if current diagnostic pathways remain unchanged, according to new projections that underscore a profound health inequality.
The scale of the disparity
The figures, from Prostate Cancer UK, estimate at least 16,000 black men will be diagnosed with the disease in the coming decade. They reflect a lifetime risk where one in four black men will receive a prostate cancer diagnosis, a rate double that of white men (one in eight) and significantly higher than Asian men (one in 13). Beyond incidence, black men are also more likely to die from the disease, with some analyses indicating they are 2.5 times more likely to do so than white men.
The reasons are multifaceted. Genetics play a role, but are compounded by a lack of awareness of the elevated risk, delays in seeking help, and barriers to accessing diagnostic tests. Furthermore, black men are more likely to be diagnosed at a late stage; one analysis found they present with stage three or four cancer at a rate 1.5 times higher than white men, limiting treatment options.
The screening impasse
This stark context makes last month’s decision by the UK National Screening Committee (UK NSC) particularly contentious. The independent body, which advises the government, rejected proposals for a targeted prostate cancer screening programme for high-risk groups, which include black men and those with a family history of the disease.
The committee’s rationale centres on a rigorous assessment of evidence, where it concluded the potential harms of widespread testing—such as over-diagnosis of slow-growing cancers and subsequent unnecessary treatment—currently outweigh the benefits for this cohort. Crucially, it cited a critical lack of UK-specific data on black patients, noting that less than 2% of participants in previous major prostate cancer screening trials were of black ethnicity, with most available data drawn from US studies.
Amy Rylance, director of health services, equity and improvement at Prostate Cancer UK, said the charity was “bitterly disappointed” by the decision. “While we accept the committee’s decision that the data they reviewed had too many gaps, a significant opportunity has been missed,” she said. The charity argues the NHS holds extensive electronic health records that could fill these evidence gaps, but this resource has not been fully utilised or reviewed by the committee.
Research, data, and a parallel recommendation
In response, Prostate Cancer UK is funding a research project to analyse NHS records for the necessary data, with results expected within a year. This effort runs alongside a larger, landmark study: the £42 million TRANSFORM trial, co-funded by the charity and the National Institute for Health and Care Research.
TRANSFORM aims to determine the best combination of tests for future screening and has a dedicated target for at least 10% of its participants to be black men, directly addressing the historical underrepresentation. Its findings, expected within two to three years, could reshape the screening landscape.
In a contrasting move, the UK NSC has made a draft recommendation to introduce targeted screening for men with confirmed BRCA1 or BRCA2 gene variants, who are also at higher risk. This programme would involve biennial screening between ages 45 and 61. The committee’s public consultation on this and the prostate cancer recommendations closed in February 2026, with a final decision pending.
“Is it because we don’t matter so much?”
For patients and families, the committee’s rejection of targeted screening for black men has sparked accusations of racial bias and profound distress. Jeff Thompson, 63, diagnosed with stage two prostate cancer in 2018, described a recovery “haunted” by mental trauma, urinary and erectile dysfunction. “I felt like we [black men] were not thought about,” he said. “If the statistics are true, then why in heaven’s name has it been declined?”
Tina Davies, who lost her father Joseph to the disease, asked: “It is as if black men are being punished for something, or they are not worth [life]… Why are men being discriminated against? Our men are dying.”
Their feelings touch on deeper issues of trust. A report by Prostate Cancer Research found up to one in three black adults have avoided seeking healthcare after a negative experience, with legacies of slavery, colonialism, and the Windrush scandal damaging trust. Nearly two-thirds of black people surveyed believed racial discrimination had prevented access to a prostate cancer test.
The Department of Health and Social Care stated: “This government wants to see screening in place for prostate cancer, provided this is backed by evidence.” It added that the UK NSC was examining the latest data thoroughly and that the government was “determined to improve outcomes,” ensuring black men “are at the heart of our research efforts.”
Prostate Cancer UK has pledged to continue working with the UK NSC to find the missing data, but has also stated that if the committee ultimately disagrees with their evidence, they will challenge the government to outline a clear plan to tackle late diagnosis and health inequalities.